Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Research & Development: ¥338 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603882 Guangzhou Kingmed Diagnostics Group Co Ltd SHSE:603882
74 GF Score
Price ¥26.71
GF Value ¥27.91
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Guangzhou Kingmed Diagnostics Group Co Research & Development?

Guangzhou Kingmed Diagnostics Group Co SHSE:603882 +0.07% 74 Research & Development is ¥338 Mil as of Mar. 2026. GuruFocus rates SHSE:603882 with a GF Score™ of 74/100 and a GF Value™ of ¥27.91 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guangzhou Kingmed Diagnostics Group Co's Research & Development for the three months ended in Mar. 2026 was ¥74 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥338 Mil.

Guangzhou Kingmed Diagnostics Group Co  (SHSE:603882) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guangzhou Kingmed Diagnostics Group Co Research & Development Related Terms

Guangzhou Kingmed Diagnostics Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Guangzhou Kingmed Diagnostics Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Kingmed Diagnostics Group Co Research & Development Chart

Guangzhou Kingmed Diagnostics Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 517.93 632.62 467.14 400.47 341.28

Guangzhou Kingmed Diagnostics Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.11 83.61 82.44 98.12 74.29
SHSE:603882
74GF Score
Guangzhou Kingmed Diagnostics Group Co Ltd SHSE:603882
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Kingmed Diagnostics Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥338 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥338 Mil mean?
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a Research & Development of ¥338 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors.
Is Guangzhou Kingmed Diagnostics Group Co's Research & Development too high?
Guangzhou Kingmed Diagnostics Group Co's current Research & Development is ¥338 Mil. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's Research & Development compare to TMO and DHR?
Guangzhou Kingmed Diagnostics Group Co's Research & Development of ¥338 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current Research & Development is ¥338 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥27.91, compared to a current price of ¥26.71 — trading 4.3% below its estimated fair value. The current Research & Development is ¥338 Mil. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current Research & Development is ¥338 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be undervalued. The current stock price of ¥26.71 is trading 4.3% below its estimated GF Value™ of ¥27.91. GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.

Key valuation signals for SHSE:603882:

  • Research & Development: ¥338 Mil
  • GF Value™: ¥27.91 vs. price of ¥26.71 (4.3% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Kingmed Diagnostics Group Co Business Description

Address International Biological Island spiral three on the 10th, Guangdong Province, Guangzhou, CHN, 510000
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score

Get the complete analysis for SHSE:603882

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.71
Price
¥27.91
GF Value